Pharmacokinetics, bioequivalence, tolerability, and effects on platelet counts of two formulations of anagrelide in healthy volunteers and patients with thrombocythemia associated with chronic myeloproliferation

Clinical Therapeutics

Volumn 31, Issue 2, 2009, Pages 386-398

  Petrides, Petro E ^a   Gisslinger, Heinz ^b   Steurer, Michael ^c   Linkesch, Werner ^d   Krumpl, Günther ^e   Schüller, Agnes ^f   Widmann, Rudolf ^f  

^a UNIVERSITY OF MUNICH   (Germany)

^b UNIVERSITY OF VIENNA   (Austria)

^c INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^d UNIVERSITY OF GRAZ   (Austria)

^e Medical Research Network GmbH   (Austria)

^f AOP Orphan Pharmaceuticals AG   (Austria)

Author keywords

3 hydroxyanagrelide; adverse event profile; anagrelide; ANAHYDRET; bioequivalence study; PT 1

Indexed keywords

2 AMINO 5,6 DICHLORO 4 DIHYDROQUINAZOLONE; 3 HYDROXYANAGRELIDE; ANAGRELIDE; DRUG METABOLITE; RL 603; THROMBOREDUCTIN; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ADULT; AGED; ANGINA PECTORIS; AREA UNDER THE CURVE; ARTICLE; AUSTRIA; BIOEQUIVALENCE; BLOOD SAMPLING; BODY MASS; CLINICAL ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DELAYED DRUG RELEASE; DIARRHEA; DISEASE ASSOCIATION; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG CAPSULE; DRUG DETERMINATION; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG FORMULATION; DRUG INDUCED HEADACHE; DRUG METABOLISM; DRUG RELEASE; DRUG SOLUBILITY; DRUG TOLERABILITY; DYSMENORRHEA; DYSPHAGIA; DYSPNEA; EDEMA; FATIGUE; FEMALE; FLU LIKE SYNDROME; FLUSHING; GERMANY; HEART PALPITATION; HEARTBURN; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HYPERBILIRUBINEMIA; IN VITRO STUDY; IN VIVO STUDY; LEUKOCYTE COUNT; LONGITUDINAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MULTICENTER STUDY; MYELOPROLIFERATIVE DISORDER; NAUSEA; PATIENT COMPLIANCE; PHARMACODYNAMICS; PHASE 1 CLINICAL TRIAL; PILOT STUDY; PROSPECTIVE STUDY; PRURITUS; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SINGLE DRUG DOSE; SWEATING; TACHYCARDIA; THROMBOCYTE COUNT; THROMBOCYTHEMIA; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT DURATION; VOLUNTEER; VOMITING;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; AREA UNDER CURVE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CHRONIC DISEASE; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; FEMALE; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; MYELOPROLIFERATIVE DISORDERS; PLATELET AGGREGATION INHIBITORS; PLATELET COUNT; QUINAZOLINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SOLUBILITY; THERAPEUTIC EQUIVALENCY; THROMBOCYTOSIS; YOUNG ADULT;

EID: 62149092192     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2009.02.008     Document Type: Article

References (32)

1. Petrides P.E. Anagrelide: A decade of clinical experience with its use for the treatment of primary thrombocythaemia. Expert Opin Pharmacother 5 (2004) 1781-1798
2. Emadi A., and Spivak J.L. Anagrelide: 20 Years later. Expert Rev Anticancer Ther 9 (2009) 37-50
3. Gaver R.C., Deeb G., Pittmani K.A., and Smyth R.D. Disposition of anagrelide, an inhibitor of platelet aggregation. Clin Pharmacol Ther 29 (1981) 381-386
4. Wang G., Franklin R., Hong Y., and Erusalimsky J.D. Comparison of the biological activities of anagrelide and its major metabolites in haematopoietic cell cultures. Br J Pharmacol 146 (2005) 324-332
5. McCarty J.M., Melone P.D., Simanis J.P., et al. A preliminary investigation into the action of anagrelide: Thrombopoietinc-Mpl receptor interactions. Exp Hematol 34 (2006) 87-96
6. Kirito K., and Kaushansky K. Transcriptional regulation of megakaryopoiesis: Thrombopoietin signaling and nuclear factors. Curr Opin Hematol 13 (2006) 151-156
7. Bender A.T., and Beavo J.A. Cyclic nucleotide phosphodiesterases: Molecular regulation to clinical use. Pharmacol Rev 58 (2006) 488-520
8. Steurer M., Gastl G., Jedrzejczak W.W., et al. Anagrelide for thrombocytosis in myeloproliferative disorders: A prospective study to assess efficacy and adverse event profile. Cancer 101 (2004) 2239-2246
9. Birgegard G., Bjorkholm M., Kutti J., et al. Adverse effects and benefits of two years of anagrelide treatment for thrombocythemia in chronic myeloproliferative disorders. Haematologica 89 (2004) 520-527
10. Harrison C.N., Campbell P.J., Buck G., et al., for the United Kingdom Medical Research Council Primary Thrombocythemia 1 Study. Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. N Engl J Med 353 (2005) 33-45
11. Gisslinger H., Gotic M., Holowiecki J., et al. Final results of the ANAHYDRET-Study: Noninferiority of anagrelide compared to hydroxyurea in newly diagnosed WHO-essential thrombocythemia patients. Blood (ASH Annual Meeting Abstracts) 112 (2008) Abstract 661
12. Agrylin (anagrelide) capsules [product information] (1997), Shire Specialty Pharmaceuticals, Wayne, Pa
13. Xagrid (anagrelide) capsules [product information] (2005), Shire Specialty Pharmaceuticals, Wayne, Pa
14. Thromboreductin (anagrelide) capsules [product information] (2008), AOP Orphan Pharmaceuticals AG, Vienna, Austria
15. Note for Guidance on Good Clinical Practice. The European Agency for the Evaluation of Medicinal Products Human Medicines Evaluation Unit (CPMP/ICH/135/95, January 17, 1997).
16. World Medical Association Declaration of Helsinki: Ethical Principles for Medical Research Involving Human Subjects. Adopted by the 18th WMA General Assembly, Helsinki, June 1964 (2000) Revised Version, Edinburgh, Scotland
17. Note for Guidance for the Investigation of Bioavailability and Bioequivalence (CPMP/EWP/QWP/1401/98 July 2001) [European Medicines Agency Web site]
18. http://www.emea.eu.int/pdfs/human/ewp/140198en.pdf Accessed October 15, 2008
19. Note for Guidance on Validation of Analytical Procedures: Methodology (CPMP/ICH/281/95) [European Medicines Agency Web site]
20. http://www.emea.europa.eu/pdfs/human/qwp/084896en.pdf Accessed January 30, 2009
21. Chow S.-C., and Liu J.P. Design and Analysis of Bioavailability and Bioequivalence Studies (1992), Marcel Dekker Inc, New York, NY
22. Brown E.G., Wood L., and Wood S. The medical dictionary for regulatory activities (MedDRA). Drug Saf 20 (1999) 109-117
23. Note for Guidance on Clinical Safety Data Management: Definitions and Standards for Expedited Reporting (CPMP/ICH/377/95)
24. http://www.emea.europa.eu/pdfs/human/ich/037795en.pdf Accessed January 10, 2008
25. European Pharmacopoiea. 6th ed (2008) Chapter 2.9.3, 267, Apparatus 2
26. Berlin N.I. Diagnosis and classification of the polycythemias. Semin Hematol 12 (1975) 339-351
27. Erusalimsky J.D., Hong Y., and Franklin R. Is the platelet lowering activity of anagrelide mediated by its major metabolite 2-amino-5,6-dichloro-3,4-dihydroquinazoline (RL603)?. Exp Hematol 30 (2002) 625-626
28. Gillespie E. Anagrelide: A potent and selective inhibitor of platelet cyclic AMP phosphodiesterase enzyme activity. Biochem Pharmacol 37 (1988) 2866-2868
29. Beavo J.A. cGMP inhibition of heart phosphodiesterase: Is it clinically relevant?. J Clin Invest 95 (1995) 445
30. James C.W. Anagrelide-induced cardiomyopathy. Pharmacotherapy 20 (2000) 1224-1227
31. Engel P.J., Johnson H., Baughman R.P., and Richards A.I. High-output heart failure associated with anagrelide therapy for essential thrombocytosis. Ann Intern Med 143 (2005) 311-313
32. Packer M., Carver J.R., Rodeheffer R.J., et al. Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group. N Engl J Med 325 (1991) 1468-1475